Cargando…

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI

Detalles Bibliográficos
Autores principales:	Matsushita, Maiko, Ozawa, Koji, Kanchi, Saori, Uchiumi, Akane, Suzuki, Takuma, Ichikawa, Daiju, Matsuki, Eri, Sakurai, Masatoshi, Karigane, Daiki, Kasahara, Hidenori, Nakajima, Hideaki, Okamoto, Shinichiro, Hattori, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649342/ http://dx.doi.org/10.1186/2051-1426-3-S2-P260

Ejemplares similares

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients
por: Matsushita, M, et al.
Publicado: (2017)

Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies
por: Matsushita, Maiko, et al.
Publicado: (2016)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

Drug Therapy in the Progressed CML Patient with multi-TKI Failure
por: Haznedaroglu, Ibrahim C.
Publicado: (2015)

Characteristics of a Novel Target Antigen against Myeloma Cells for Immunotherapy
por: Matsushita, Maiko, et al.
Publicado: (2020)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
por: Ramdial, Jeremy L., et al.
Publicado: (2019)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
por: Muselli, Fabien, et al.
Publicado: (2021)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation
por: Bedel, Aurélie, et al.
Publicado: (2013)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
por: Luan, Chengxin, et al.
Publicado: (2022)

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2017)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model
por: Cheng, Shan, et al.
Publicado: (2021)

Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
por: Herrmann, Andreas B., et al.
Publicado: (2020)

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
por: Semerad, Lukas, et al.
Publicado: (2023)

Successful treatment of breakthrough disseminated Trichosporon asahii fungemia in a patient with acute myeloid leukemia receiving itraconazole prophylaxis
por: Karigane, Daiki, et al.
Publicado: (2017)

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
por: Lin, Hanyang, et al.
Publicado: (2014)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients
por: Lavrov, Alexander V., et al.
Publicado: (2019)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
por: Kim, Nayoung, et al.
Publicado: (2020)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
por: Papalexandri, Apostolia, et al.
Publicado: (2018)

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice
por: Chen, Yilin, et al.
Publicado: (2023)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
por: Matsushita, Maiko, et al.
Publicado: (2023)

Very Late Relapse of Acute Promyelocytic Leukemia 17 Years after Continuous Remission
por: Sakurai, Masatoshi, et al.
Publicado: (2018)

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)
por: Fujisawa, Shin, et al.
Publicado: (2018)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
por: Richter, Johan, et al.
Publicado: (2021)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
por: Imeri, Jusuf, et al.
Publicado: (2023)

Long-term reduction in the incidence of aplastic anemia and immune thrombocytopenia during the COVID-19 pandemic
por: Sakurai, Masatoshi, et al.
Publicado: (2023)

CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI
por: Moreno-Lorenzana, Dafne, et al.
Publicado: (2016)

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
por: Pavlovsky, Carolina, et al.
Publicado: (2023)

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer
por: Makita, Yuji, et al.
Publicado: (2018)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation
por: Yang, Taewoo, et al.
Publicado: (2022)

Mallory‐Weise syndrome in a patient treated with EGFR‐TKI
por: Okauchi, Shinichiro, et al.
Publicado: (2017)

Cytogenetic study in CML
por: Subramanian, P.G.
Publicado: (2012)

CML: Evolution and design
por: Murray-Rust, Peter, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m21brvho7hva7dh2vaov1qsg10